In a nursing home! Lilly launches phase III clinical trials of the new coronavirus neutralizing antibody.

Read: Lilly's new coronavirus antibody drug has launched Phase III BLAZE-2 trials in the United States.
just like the new crown vaccine, antibody-based new-crown drugs are moving at an unprecedented rate.
these antibody drugs have the potential to help prevent new coronavirus infections and treat COVID-19 in older populations with poor response to vaccines or populations with weak immune systems.
Although any benefits of vaccines and antibodies may be temporary, antibody drugs work quickly, meaning they can prevent infection or worsen the condition of patients with neo-coronary pneumonia who have developed symptoms.
if proven in clinical trials, these antibody drugs would be a boon for the healthcare system, at least as a bridge to help patients transition to a safe and effective vaccine.
However, it is not clear whether such antibody drugs will meet expectations.
No company has reported data on the effectiveness of human trials, although several drugmakers are rapidly developing new crown antibody drugs, including Lilly, Regenerative, AbbVie, AstraZeneca and Vir Biotechnology.
in the research and development of antibody drugs, Lilly and Regenerative Yuan have become the industry leader.
last month, the Regeneration Element initiated a Phase III trial based on a retrospective analysis of safety data from a small study.
now Lilly has made a similar decision, launching a Phase III study after early tests found that its antibody drugs were "well tolerated at all test doses."
, according to a press release from Lilly, the company has launched a Phase III BLAZE-2 trial in the United States, with the help of the U.S. government, mainly in people with high risk of infection and poor health , residents and staff in long-term care facilities (usually nursing homes and assisted living communities) to test and test whether the antibody LY-CoV555 can prevent new crown virus infection and treat COVID-19.
More than 40 percent of COVID-19 deaths in the United States are linked to outbreaks in long-term care facilities, according to an analysis by The New York Times.
LY-CoV555, developed by Lilly in collaboration with Canadian biotech company AbCellera, is a monoclonal antibody with a strong neutralizing effect on SARS-CoV-2 rata protein sesame from blood samples taken from the first COVID-19 rehabilitation in the United States.
typically, drugmakers conduct research through experienced test sites, such as large medical centers, which have the tools and materials to conduct complex medical experiments.
for BLAZE-2, Lilly and the National Institutes of Health's COVID-19 Prevention Network (CoVPN) are using modified recreational vehicles (RVs) as on-site infusion clinics in nursing homes involved in the study.
with these RV fleets, Lilly's goal is to respond quickly to hot areas of the disease and recruit 2,400 nursing home residents or staff.
the trial will test whether a single dose of LY-CoV555 can reduce the rate of coronavirus infection within 4 weeks and COVID-19 complications within 8 weeks.
Lilly has two other studies under way: a Phase I trial of hospitalized COVID-19 patients, and a Phase II study of BLAZE-1 involving 400 patients, the latter of which was a light and moderate patient recently diagnosed with COVID-19.
Lilly is expected to complete the BLAZE-1 entry in September, after which preliminary results will be released and full data available in the fourth quarter.
at this time, Lilly has not provided a timetable for the BLAZE-2 trial. A spokesman for
said data disclosure in Phase II and Phase III trials was highly dependent on patient admission.
Lilly also said two other Phase III studies will be conducted on PATIENTs with COVID-19 who are in the hospital with moderate or severe hospitalization.
the company expects 100,000 doses of LY-CoV555 by the end of the year if the drug proves to be effective.
at the same time, Lilly's partner in China, Junshi Bio, in June has promoted another antibody drug, JS016, to phase I clinical trials in humans.
JS016 is also rapidly screened from the body of patients in rehab and recombined in vitro to express a high lysmic and capable of all-human monoclonal antibodies.
in preclinical in vitro and rhesus monkey susmos, JS016 demonstrated good neutralactivity and blocking ability, demonstrating the therapeutic and prevention potential of anti-neo-coronavirus.
mid-July, Junshi Bio announced that all subjects in the Phase I trial in China had completed administration of the drug, and no dose-restriction events had been observed so far.
as the first new clinical lymic virus neutralizing antibodies in China, JS016 is at the world's leading research and development progress, its clinical trials in the United States also launched in the second quarter.
Reference Source: 1. Lilly starts phase 3 test of COVID-19 antibody in nursing homes 2. Lilly to test COVID-19 antibody drug in un nursorthodoxing home study.